Despite IV Vancomycin’s Stronghold on the MRSA Antibiotic Hospital Market, Surveyed ID Specialists Report Shifting Away from IV Vancomycin to Branded Agents, Including Pfizer’s Zyvox and Cubist/Novartis’s Cubicin

EXTON, Pa.--(BUSINESS WIRE)--BioTrends and AMR release annual report that provides insight into the treatment of patients with MRSA and other Serious Gram-positive infections in the hospital setting…